Literature DB >> 22118829

Structure based drug design, synthesis and evaluation of 4-(benzyloxy)-1-phenylbut-2-yn-1-ol derivatives as 5-lipoxygenase inhibitors.

Nimmanapalli P Reddy1, T Chandramohan Reddy, Polamarasetty Aparoy, Chandrani Achari, P Ramu Sridhar, Pallu Reddanna.   

Abstract

A group of 4-(benzyloxy)-1-phenylbut-2-yn-1-ol derivatives were designed using Site point connection method, synthesized and evaluated for their 5-Lipoxygenase (5-LOX) inhibitory activity. Hydrophobic site points in 5-LOX were considered for the study and substitutions were planned such that 4k will have strong hydrophobic group in the corresponding site point. Biological results supported the in silico prediction with compound 4k exhibiting good inhibition with IC(50) value of 8 μM against 5-LOX. The compounds 4j and 4k showed potent cytotoxic effects against various cancer cell lines (COLO-205, MDA-MB-231 and HepG2) but with no effect on normal cell line (HaCaT). The overall trend showed 4k as the most potent compound. Further studies demonstrated the protective effect of 4k in mouse Acute Lung Injury (ALI) model induced by lipopolysaccharide (LPS).
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118829     DOI: 10.1016/j.ejmech.2011.11.003

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

Review 1.  Recent development of lipoxygenase inhibitors as anti-inflammatory agents.

Authors:  Chaoyu Hu; Shutao Ma
Journal:  Medchemcomm       Date:  2017-11-29       Impact factor: 3.597

Review 2.  Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors.

Authors:  Polamarasetty Aparoy; Kakularam Kumar Reddy; Pallu Reddanna
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  Structural optimization and biological evaluation of 1,5-disubstituted pyrazole-3-carboxamines as potent inhibitors of human 5-lipoxygenase.

Authors:  Yu Zhou; Jun Liu; Mingyue Zheng; Shuli Zheng; Chunyi Jiang; Xiaomei Zhou; Dong Zhang; Jihui Zhao; Deju Ye; Mingfang Zheng; Hualiang Jiang; Dongxiang Liu; Jian Cheng; Hong Liu
Journal:  Acta Pharm Sin B       Date:  2016-01-07       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.